Human Psychopharmacology: Clinical and Experimental

Author Guidelines

Author Guidelines

1. AIMS & SCOPE

Human Psychopharmacology: Clinical and Experimental provides a forum for the evaluation of clinical and experimental research on both new and established psychotropic medicines. Experimental studies of other centrally active drugs, including herbal products, in clinical, social and psychological contexts, as well as clinical/scientific papers on drugs of abuse and drug dependency will also be considered. While the primary purpose of the Journal is to publish the results of clinical research, the results of animal studies relevant to human psychopharmacology are welcome. The following topics are of especial interest to the editors and readers of the Journal:

• All aspects of clinical psychopharmacology
• Efficacy and safety studies of novel and standard psychotropic drugs
• Studies of the adverse effects of psychotropic drugs
• Effects of psychotropic drugs on normal physiological processes
• Geriatric and paediatric psychopharmacology
• Ethical and psychosocial aspects of drug use and misuse
• Psychopharmacological aspects of sleep and chronobiology
• Neuroimaging and psychoactive drugs
• Phytopharmacology and psychoactive substances
• Drug treatment of neurological disorders
• Mechanisms of action of psychotropic drugs
• Ethnopsychopharmacology
• Pharmacogenetic aspects of mental illness and drug response
• Psychometrics: psychopharmacological methods and experimental design

Further information about the Journal, including links to the online sample copy and contents pages, can be found on the Journal homepage .

2. MANUSCRIPT CATEGORIES

Human Psychopharmacology invites the following types of submission:

Research Articles

Research Articles are the Journal’s primary mode of scientific communication. Peer review of Research Articles will be handled by the most appropriate Editor .

Review Articles

Authors who wish to submit an unsolicited review should first contact one of the Editors to determine its suitability for publication in the Journal. All Reviews will be peer-reviewed.

Short Communications

Short research pieces and practical inferences from clinical observations will be considered, but should not exceed 1500 words. All Short Communications are peer-reviewed. Human Psychopharmacology will not accept Case Reports.

3. MANUSCRIPT SUBMISSION

All submissions should be made online at the Human Psychopharmacology ScholarOne Manuscripts site (formerly known as Manuscript Central)— http://mc.manuscriptcentral.com/hup . New users should first create an account. Once a user is logged onto the site, submissions should be made via the Author Centre.

At the same time as manuscript submission, authors must also submit electronically:

• permission grants—if the manuscript contains extracts, including illustrations, from other copyright works (including material from on-line or intranet sources) it is the author's responsibility to obtain written permission from the owners of the publishing rights to reproduce such extracts using the Wiley Permission Request Form .

4. MANUSCRIPT PREPARATION

Manuscripts must be written in English.

Text should be supplied in a format compatible with Microsoft Word for Windows (PC). Charts and tables are considered textual and should also be supplied in a format compatible with Word. All figures (illustrations, diagrams, photographs) should be supplied in jpg, tiff or eps format.

All manuscripts must be typed in 12pt font and in double space with margins of at least 2.5 cm.

Manuscripts must comply with the word limits defined in section 2, and include:

Title Page

The first page of the manuscript should contain the following information:

• the title of the paper
• a running head not exceeding 50 characters
• 2–6 article keywords for indexing purposes
• names of authors
• names of the institutions at which the research was conducted
• name, address, telephone and fax number, and email address of corresponding author
• the name(s) of any sponsor(s) of the research contained in the paper, along with grant number(s)

Structured Abstracts

Authors submitting Research and Review Articles should note that structured abstracts (maximum 200 words) are required. The structured abstract should adopt the format: Objective, Methods, Results, Conclusions. (Authors of Reviews may use Design instead of Method.) Abstracts should contain no citation to other published work.

Text

This should in general, but not necessarily, be divided into sections with the headings: Introduction, Methods, Results, Discussion, Conclusion.

Generic or chemical names should be used for all compounds.

Tables and Figures

Tables and figures should not be inserted in the appropriate place in the text but should be included at the end of the paper, each on a separate page.

Tables and figures should be referred to in text as follows: Figure 1, Figure 2; Table 1, Table 2. The place at which a table or figure is to be inserted in the printed text should be indicated clearly on a manuscript. Each table and/or figure must have a legend that explains its purpose without reference to the text.

The cost of printing colour illustrations in the Journal will be charged to the author at £600 per page. Colour figures may appear in the online edition free of charge.

References

References should be in 'Harvard' format, i.e, names and dates in brackets in the text (Jones, 2000; Smith and Jones, 2001; Jones et al ., 2002), and the full reference listed at the end of the paper, in alphabetical order by first author, as follows:

Taylor D, Paton C, Kerwin R. 2003. The Maudsley Prescribing Guidelines . Martin Dunitz: London.

Rabbitt PMA. 1982. How do old people know what to do next? In Aging and Cognitive Processes , Craik FIM, Trehub S (eds). Plenum Press: New York; 79-98.

Baune BT, Caliskan S, Todder T. 2007. Effects of adjunctive antidepressant therapy with quetiapine on clinical outcome, quality of sleep and daytime motor activity in patients with treatment-resistant depression. Hum Psychopharmacol 22 : 1–9.

(Titles of periodicals should be abbreviated according to the style used in Index Medicus.)

5. DECLARATION

Original Publication

Submission of a manuscript will be held to imply that it contains original unpublished work and is not being submitted for publication elsewhere at the same time. The author must supply a full statement to the Editor-in-Chief about all submissions and previous reports that might be regarded as redundant or duplicate publication of the same or very similar work.

Conflict of Interest

Authors are responsible for disclosing all financial and personal relationships between themselves and others that might bias their work. To prevent ambiguity, authors must state explicitly whether potential conflicts do or do not exist. Investigators should disclose potential conflicts to study participants and should state in the manuscript whether they have done so. Authors should describe the role of the study sponsor(s), if any, in study design, in the collection, analysis and interpretation of data, in the writing of the report and in the decision to submit the report for publication. If the supporting source had no such involvement, the authors should so state.

Ethics

When reporting experiments on human subjects, indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional or regional) and with the Helsinki Declaration of 1975, as revised in 1983. Do not use patients' names, initials or hospital numbers, especially in illustrative material. When reporting experiments on animals, indicate whether the institution's or a national research council's guide for, or any national law on, the care and use of laboratory animals was followed. A statement describing explicitly the ethical background to the studies being reported should be included in all manuscripts in the Materials and Methods section. Ethics committee or institutional review board approval should be stated.

Patients have a right to privacy that should not be infringed without informed consent. Identifying information should not be published in written descriptions, photographs and pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication. Informed consent for this purpose requires that the patient be shown the manuscript to be published. Identifying details should be omitted if they are not essential but patient data should never be altered or falsified in an attempt to attain anonymity. Complete anonymity is difficult to achieve and informed consent should be obtained if there is any doubt. For example, masking the eye region in photographs of patients is inadequate protection of anonymity.

Authorship

All persons designated as authors should qualify for authorship and all those who qualify should be listed. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content. One or more authors should take responsibility for the integrity of the work as a whole, from inception to published article. Authorship credit should be based only on 1) substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; 3) final approval of the version to be published. Conditions 1, 2 and 3 must all be met. Acquisition of funding, the collection of data or general supervision of the research group, by themselves, do not justify authorship. All others who contributed to the work who are not authors should be named in the Acknowledgements section.

Committee on Publication Ethics (COPE)

As a member of the Committee on Publication Ethics (COPE), adherence to these submission criteria is considered essential for publication in Human Psychopharmacology ; mandatory fields are included in the online submission process to ensure this. If, at a later stage in the submission process or even after publication, a manuscript or authors are found to have disregarded these criteria, it is the duty of the Editor-in-Chief to report this to COPE. COPE may recommend that action may be taken, including but not exclusive to, informing the authors' professional regulatory body and/or institution of such a dereliction.

The website for COPE may be accessed at: http://www.publicationethics.org.uk

6. ADDITIONAL INFORMATION ON ACCEPTANCE

Copyright

If your paper is accepted, the author identified as the formal corresponding author for the paper will receive an email prompting them to login into Author Services; where via the Wiley Author Licensing Service (WALS) they will be able to complete the license agreement on behalf of all authors on the paper. The corresponding author MUST submit the CTA as it is a requirement for publication.

For authors signing the copyright transfer agreement
If the OnlineOpen option is not selected the corresponding author will be presented with the copyright transfer agreement (CTA) to sign. The terms and conditions of the CTA can be previewed in the samples associated with the Copyright FAQs below:

CTA Terms and Conditions http://authorservices.wiley.com/bauthor/faqs_copyright.asp

For authors choosing OnlineOpen
If the OnlineOpen option is selected the corresponding author will have a choice of the following Creative Commons License Open Access Agreements (OAA):

Creative Commons Attribution License OAA
Creative Commons Attribution Non-Commercial License OAA
Creative Commons Attribution Non-Commercial -NoDerivs License OAA

To preview the terms and conditions of these open access agreements please visit the Copyright FAQs hosted on Wiley Author Services and visit http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html..

If you select the OnlineOpen option and your research is funded by The Wellcome Trust and members of the Research Councils UK (RCUK) you will be given the opportunity to publish your article under a CC-BY license supporting you in complying with Wellcome Trust and Research Councils UK requirements. For more information on this policy and the Journal’s compliant self-archiving policy please visit: http://www.wiley.com/go/funderstatement.

Proofs

Proofs of accepted articles will be sent to the author for checking. This stage is to be used only to correct errors that may have been introduced during the production process. Prompt return of the corrected proofs, preferably within two days of receipt, will minimise the risk of the paper being held over to a later issue.

Offprints

Free access to the final PDF offprint of your article will be available via Author Services only. Please therefore sign up for Author Services if you would like access to your article PDF offprint and enjoy the many other benefits the service offers.

Early View

Early View is Wiley's exclusive service presenting individual articles online as soon as they are ready before the release of the compiled print issue. Early View articles are complete, citable and are published in an average time of 6 weeks from acceptance.

OnlineOpen

OnlineOpen is available to authors of primary research articles who wish to make their article available to non-subscribers on publication, or whose funding agency requires grantees to archive the final version of their article. With OnlineOpen, the author, the author's funding agency, or the author's institution pays a fee to ensure that the article is made available to non-subscribers upon publication via Wiley Online Library, as well as deposited in the funding agency's preferred archive. For the full list of terms and conditions, see http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms.

Authors wishing to publish via OnlineOpen will be required to complete the payment form available from our website at: https://onlinelibrary.wiley.com/onlineOpenOrder.

Prior to acceptance there is no requirement to inform the Editorial Office that you intend to publish your paper OnlineOpen if you do not wish to. All OnlineOpen articles are treated in the same way as any other article. They go through the journal's standard peer-review process and will be accepted or rejected based on their own merit.

Note to NIH Grantees

Pursuant to NIH mandate, Wiley-Blackwell will post the accepted version of contributions authored by NIH grant-holders to PubMed Central upon accceptance. This accepted version will be made publicly available 12 months after publication. For further information, click here